Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173221 | 0.84 | LMNA (0.40) | LMNASMN1; SMN2MTNR1AMTNR1BCACNA1H | |
| SCHEMBL2172802 | 0.78 | LMNA (0.44) | LMNASMN1; SMN2CACNA1HCYP19A1ATM | |
| SCHEMBL2172795 | 0.78 | CACNA1H (0.47) | LMNASMN1; SMN2MTNR1AMTNR1BCACNA1H | |
| SCHEMBL16629273 | 0.67 | BRD4 (0.35) | HTR2CSLC6A4 | |
| SCHEMBL15784061 | 0.66 | TTK (0.41) | LMNAMTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL29632640 | 0.66 | TTK (0.41) | LMNAMTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL30298020 | 0.66 | CACNA1H (0.48) | SMN1; SMN2CACNA1HCYP19A1L3MBTL1MEN1 | |
| SCHEMBL24035218 | 0.66 | HTR2C (0.40) | SMN1; SMN2CACNA1HHTR2CSLC6A4L3MBTL1 | |
| SCHEMBL3915767 | 0.66 | ALDH1A1 (0.42) | LMNAMTNR1AMTNR1BCYP19A1L3MBTL1 | |
| SCHEMBL15156318 | 0.66 | ALDH1A1 (0.46) | LMNAMTNR1AMTNR1BL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | LMNA 1122/4885SMN1; SMN2 2298/4885MTNR1A 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.